Last reviewed · How we verify

NCT03643302

Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation

Completed Last updated 8 October 2020
What this trial tests

trial testing Version BF-1T26 electronic bronchoscope in Bronchiectasis Adult in 189 participants. Completed in 18 March 2019.

Timeline
1 February 2018
Primary endpoint
28 February 2019
18 March 2019

Quick facts

Lead sponsorShanghai Pulmonary Hospital, Shanghai, China
StatusCompleted
Study typeOBSERVATIONAL
Enrollment189
Start date1 February 2018
Primary completion28 February 2019
Estimated completion18 March 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 18 to 80, any sex, with Bronchiectasis Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

No study have evaluated the efficacy and safety of airway clearance therapy (ACT) and bronchoalveolar lavage (BAL) under bronchoscope for bronchiectasis. This study aimed to evaluate the clinical efficacy and safety of tran-bronchoscopy airway clearance and bronchoalveolar lavage in the treatment of moderate to severe bronchiectasis with acute exacerbation:A randomized, prospective cohort study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Bronchoscopic airway clearance therapy for acute exacerbations of bronchiectasis.
    Liu Y, Lu HW, Gu SY, Wang WW, et al · · 2021 · cited 6× · PMID 34537448 · DOI 10.1016/j.ebiom.2021.103587

Verify or expand the search:

Other recruiting trials for Bronchiectasis Adult

Currently open trials in the same condition.

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03643302.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing